An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could provide an effective treatment against RSV disease, according to researchers in the Center for Translational Antiviral Research at Georgia State University.
Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
June 26, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022